[1]
|
H. Caner, E. Groner, L. Levy and I. Agranat, “Trends in the Development of Chiral Drugs,” Drug Discovery Today, Vol. 9, No. 3, 2004, pp. 105-110.
doi:10.1016/S1359-6446(03)02904-0
|
[2]
|
J. Caldwell, “Importance of Stereospecific Bionalytical Monitoring in Drug Development,” Journal of Chromatography A, Vol. 719, No. 1, 1996, pp. 3-13.
doi:10.1016/0021-9673(95)00465-3
|
[3]
|
N. M. Maier, P. Franco and W. Lindner, “Separation of Enantiomers: Needs Challenges, Perspectives,” Journal of Chromatography A, Vol. 906, No. 3, 2001, pp. 3-33.
doi:10.1016/S0021-9673(00)00532-X
|
[4]
|
T. E. Beesley and R. P. W. Scott, “Chiral Chromatography,” John Wiley & Sons, Ltd., New York, 1998, pp. 23-26.
|
[5]
|
E. Leitersdorf, “Selective Cholesterol Absorption Inhibition: A Novel Strategy in Lipid-Lowering Management,” International Journal of Clinical Practice, Vol. 56, No. 2, 2002, pp. 116-119.
|
[6]
|
M. Von Heek, C. Farley and D. S. Compton, “Ezetimibe Selectively Inhibits Intestinal Cholesterol Absorption in Rodents in Presence and Absence of Exocrine Pancreatic Function,” British Journal of Pharmacology, Vol. 134, No. 2, 2001, pp. 409-417.
|
[7]
|
S. Singh, B. Singh, R. Bahuguna, L. Wadhwa and R. Saxena, “Stress Degradation Studies on Ezetimibe and Development of a Validated Stability-Indicating HPLC Assay,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 41, No. 3, 2006, pp. 1037-1040.
doi:10.1016/j.jpba.2006.01.030
|
[8]
|
R. Sistla, V. S. Tata, Y. V. Kashyap, D. Chandrasekar and P. V. Diwan, “Development and Validation of a Reversed-Phase HPLC Method for the Determination of Ezetimibe in Pharmaceutical Dosage Forms,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 39, No. 3-4, 2005, pp. 517-522.
doi:10.1016/j.jpba.2005.04.026
|
[9]
|
T. L. Chester, “The Role of Supercritical Fluid Chromatography in Analytical Chemistry,” Journal of Chromatographic Science, Vol. 24, No. 6, 1986, pp. 226-229.
doi:10.1093/chromsci/24.6.226
|